Cyclacel Pharmaceuticals Files 8-K Report
Ticker: BGMSP · Form: 8-K · Filed: Jul 7, 2025 · CIK: 1130166
Sentiment: neutral
Topics: material-agreement, disclosure, financials
Related Tickers: CYCC
TL;DR
Cyclacel Pharma (CYCC) filed an 8-K on 7/7/25 - material agreement, Reg FD, financials.
AI Summary
On July 7, 2025, Cyclacel Pharmaceuticals, Inc. filed an 8-K report detailing a material definitive agreement. The filing also includes Regulation FD disclosures and financial statements and exhibits. The company is incorporated in Delaware and its fiscal year ends on December 31.
Why It Matters
This 8-K filing indicates significant corporate activity or a material event has occurred for Cyclacel Pharmaceuticals, Inc., requiring public disclosure.
Risk Assessment
Risk Level: low — This is a standard 8-K filing reporting a material definitive agreement and other disclosures, not indicating immediate financial distress or significant operational changes.
Key Numbers
- 0001130166 — Central Index Key (Unique identifier for the filer)
- 2834 — Standard Industrial Classification (Industry code for Pharmaceutical Preparations)
Key Players & Entities
- Cyclacel Pharmaceuticals, Inc. (company) — Registrant
- July 7, 2025 (date) — Date of Report
- Delaware (jurisdiction) — State of Incorporation
- 0-50626 (filing_number) — Commission File Number
- 91-1707622 (ein) — I.R.S. Employer Identification Number
FAQ
What is the specific nature of the material definitive agreement mentioned in the 8-K filing?
The filing indicates an 'Entry into a Material Definitive Agreement' as an item information, but the specific details of the agreement are not provided in the provided text.
What are the key exhibits included with this 8-K filing?
The filing lists 'Financial Statements and Exhibits' as an item information, but the specific exhibits are not detailed in the provided text.
When was Cyclacel Pharmaceuticals, Inc. previously known as XCYTE THERAPIES INC?
The date of the name change from XCYTE THERAPIES INC to Cyclacel Pharmaceuticals, Inc. was December 18, 2000.
What is the business address and phone number for Cyclacel Pharmaceuticals, Inc.?
The business address is 200 Connell Drive, Suite 1500, Berkeley Heights, NJ 07922, and the business phone number is 908-517-7330.
What is the fiscal year end for Cyclacel Pharmaceuticals, Inc.?
The fiscal year end for Cyclacel Pharmaceuticals, Inc. is December 31.
Filing Details
This Form 8-K (Form 8-K) was filed with the SEC on July 7, 2025 regarding Cyclacel Pharmaceuticals, Inc. (BGMSP).